Thursday, April 14, 2016 9:12:31 AM
So I've decided to put my money where my mouth is and go short. Not a very large amount of my NPV, but you know--enough to beat a table full of stuck players, that's for sure ;)
The fundamentals and risks here are just really horrible. The latest UCLA thing tells me something bad too. But I won't get into all that. You all see it as bullish. Okay.
Let's see what happens. It's been my experience that those who are stuck and really FEEL IT will never capitulate until they've lost it all.
Perhaps you can comment on this in light of your other predictions back in December (e.g. your first pick CMRX was around $35 in December, closed yesterday at $5.67!)
Pyrrhonian Sunday, 12/27/15 07:36:33 PM Post # 48689
In contrast with NWBO's dismal prospects, I much prefer CMRX, ACHN, and RUSL. They're my biggies. Trading around AEZS (de risk before topline), like CYTR (not too heavy, but liking their chances of hitting SS PFS, which in 2nd like sarcoma with no real SOC is totally acceptable--unlike in NWBO's trial--will derisk somewhat before topline too), like ARGS, mostly for trading and to hold through data read out of their up and coming small studies, in particular combining AGS-003 with anti PD1. Another de risk before topline play, but that'll be a while. Bit concerned about up coming dilution but the huge sell off provided too juicy an opportunity. CLBS I'm long, after I got stopped out a bunch of times, so far sporting about a 25% loss, but given my weird history with that co it should be much worse. Stopped out of ARGS once too but held off until recently. Up a little there.
Was long YANG for a while. Not shorting anything else at the mom. Will short GILD at some point. Also plan to short LNKD again at some point.
Had to mention NWBO in this post otherwise off topic. Not trying to bash every chance I get ;)
Man am I being nice here.
Recent NWBO News
- How Advanced Drug Delivery Could Improve Existing Cancer Treatments • GlobeNewswire Inc. • 06/01/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
